等待开盘 10-06 09:30:00 美东时间
+0.270
+2.25%
Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.
09-23 01:55
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
07-21 23:44
The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young Thomas, and Joseph M. Terranova.
07-09 19:45
US stocks decline on Tuesday, with Nasdaq falling 0.61% and S&P 500 dropping 0.24%. Consumer staples shares rise 1.8% while tech stocks fall 2.1%. Logistics Manager's Index records strongest growth since March 2022.
07-08 01:06
Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.
07-07 20:24
Vertex (NASDAQ:VERX) reported quarterly earnings of $0.17 per share which met the analyst consensus estimate. This is a 13.33 percent increase over earnings of $0.15 per share from the same period last year. The company
05-07 19:08
Artificial intelligence dominates market conversations, spawning two competing investment narratives. One rides on blockchain promises and decentralized computing dreams. The other ships actual chips, generates billions in profit, and pays real dividends. As we head toward 2026, the gap between AI cryptocurrency tokens and traditional AI stocks isn’t just wide.
2025-12-16 00:53
Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's Halftime Report. FDA extended review for TransCon CNP.
2025-12-09 21:16
Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH meeting.
2025-12-08 21:17
登录新浪财经APP 搜索【信披】查看更多考评等级 (来源:招商证券策略研究) 张夏 S1090513080006 李昊阳(产业趋势、主题投资...
2025-11-25 20:48